OSR Holdings, Inc. (NASDAQ:OSRH) Short Interest Update

OSR Holdings, Inc. (NASDAQ:OSRH) was the recipient of a significant decrease in short interest during the month of July. As of July 31st, there was short interest totaling 1,048,980 shares, a decrease of 38.1% from the July 15th total of 1,693,343 shares. Approximately 4.7% of the company’s shares are sold short. Based on an average daily trading volume, of 705,294 shares, the days-to-cover ratio is currently 1.5 days.

OSR Stock Performance

Shares of OSR stock traded down $0.03 on Wednesday, reaching $0.40. The company had a trading volume of 18,545,935 shares, compared to its average volume of 6,670,427. The firm’s 50 day moving average price is $0.39 and its two-hundred day moving average price is $0.47. OSR has a 52-week low of $0.25 and a 52-week high of $1.24. The firm has a market cap of $14.19 million, a PE ratio of -1.08 and a beta of 0.55.

OSR (NASDAQ:OSRH) last released its quarterly earnings results on Friday, August 14th. The company reported ($0.02) EPS for the quarter. The firm had revenue of $0.32 million for the quarter. OSR had a negative return on equity of 8.28% and a negative net margin of 593.15%.

Institutional Inflows and Outflows

A hedge fund recently bought a new position in OSR stock. Susquehanna International Group LLP purchased a new stake in OSR Holdings, Inc. (NASDAQ:OSRH) during the third quarter, according to the company in its most recent disclosure with the SEC. The firm purchased 79,807 shares of the company’s stock, valued at approximately $43,000. Susquehanna International Group LLP owned approximately 0.37% of OSR at the end of the most recent reporting period. Institutional investors own 55.30% of the company’s stock.

Wall Street Analysts Forecast Growth

Several equities analysts have issued reports on the stock. Wall Street Zen raised shares of OSR from a “strong sell” rating to a “sell” rating in a report on Saturday, April 25th. Weiss Ratings reissued a “sell (e+)” rating on shares of OSR in a research report on Wednesday, June 24th. One analyst has rated the stock with a Sell rating, Based on data from MarketBeat.com, the company currently has an average rating of “Sell”.

About OSR

OSR Holdings leverages its international network of partners in the US, Europe, and South Korea to market and license its pipeline of proprietary platform technologies for broad application to efficient clinical trial programs, with the ultimate goal of addressing unmet medical needs. We partner with biotherapeutics companies with innovative and proprietary drug R&D “platform technologies” versus “assets only” companies, whose commercial viability is heavily dependent on positive results for individual treatment modalities in extremely rigorous and time consuming clinical trials.